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The Ras oncogene products regulate the expression of genes in transformed cells, and members of the Ets
family of transcription factors have been implicated in this process. To determine which Ets factors are the
targets of Ras signaling pathways, the abilities of several Ets factors to activate Ras-responsive enhancer
(RRE) reporters in the presence of oncogenic Ras were examined. In transient transfection assays, reporters
containing RREs composed of Ets–AP-1 binding sites could be activated 30-fold in NIH 3T3 fibroblasts and
80-fold in the macrophage-like line RAW264 by the combination of Ets1 or Ets2 and Ras but not by several
other Ets factors that were tested in the assay. Ets2 and Ras also superactivated an RRE composed of Ets-Ets
binding sites, but the Ets-responsive promoter of the c-fms gene was not superactivated. Mutation of a
threonine residue to alanine in the conserved amino-terminal regions of Ets1 and Ets2 (threonine 38 and
threonine 72, respectively) abrogated the ability of each of these proteins to superactivate reporter gene
expression. Phosphoamino acid analysis of radiolabeled Ets2 revealed that Ras induced normally absent
threonine-specific phosphorylation of the protein. The Ras-dependent increase in threonine phosphorylation
was not observed in Ets2 proteins that had the conserved threonine 72 residue mutated to alanine or serine.
These data indicate that Ets1 and Ets2 are specific nuclear targets of Ras signaling events and that phos-
phorylation of a conserved threonine residue is a necessary molecular component of Ras-mediated activation
of these transcription factors.
The Ras gene products are GTP-dependent molecular
switches essential for growth of cultured cells (3, 45). The Raf
proto-oncogene product directly interacts with Ras in a GTP-
dependent manner (47, 48, 56), identifying a long-sought ef-
fector of Ras action. The Raf kinase can activate MEK kinases,
which in turn activate the mitogen-activated kinase (MAP)
kinase family (13, 14, 24). Activation of this protein kinase
cascade is critical for Ras to exert effects on differentiation and
cell growth (10, 36). Among the targets of Ras-triggered pro-
tein kinase cascades in cells are nuclear transcription factors
which regulate genes that ultimately confer specific cellular
phenotypes (reviewed in references 5, 20, and 27). Two fami-
lies in particular, the Ets and AP-1/ATF families of transcrip-
tion factors, have been identified as key nuclear mediators of
Ras action.
The Ets family of transcription factors are related to the
oncogene first identified in the chicken E26 retrovirus and
share a highly conserved DNA-binding motif termed the Ets
domain (26). The Ets factor Elk-1/SAP-1 regulates the c-fos
promoter through formation of a ternary complex with the
serum response factor (11). Elk-1 is a target of MAP kinases
p42 and p44, and phosphorylation of the C-terminal portion of
the protein leads to a stimulation of transactivation by the
Elk-1–serum response factor complex (23, 35). Likewise, the
Drosophila Ets factor Pointed has recently been shown by ge-
netic criteria to be a direct target for Ras-MAP kinase signal-
ing during eye development in the fly, although actual gene
targets of this factor have not been identified (8, 28, 38). In
addition to the Ets domain, Pointed contains a region of ap-
proximately 100 amino acids, termed the Pointed domain, that
is highly conserved within a subgroup of Ets factors, in partic-
ular with Ets1 and Ets2 (29, 52). This Pointed domain region
contains a threonine residue at position 151 that is phosphor-
ylated in vitro by Drosophila MAP kinase (8), and a Pointed
protein engineered to contain an alanine residue at threonine
151 could not transactivate a reporter gene in a Ras-dependent
fashion (8, 38).
Both of the AP-1 family members c-fos and c-jun encode
products whose transactivation potential can be enhanced by
Ras via a molecular mechanism that depends on phosphory-
lation of specific residues in these transcription factors (4, 12,
44). Kinases that mediate the phosphorylation of c-Jun (JNK
kinases) have been identified and molecularly cloned. These
are members of the MAP kinase superfamily but distinct from
the best-characterized members of the MAP kinase family,
pp42 and pp44 (15, 22), and apparently regulated by a distinct
effector pathway as well (37). The Ras-activated kinase that
stimulates the activity of the transcription factor c-Fos appears
to be distinct from JNK or MAP kinases p42 and p44 (12). In
addition, the CREB/ATF factor has been demonstrated to be
a target of Ras signaling in PC12 cells via an apparently unique
kinase (19). Thus, Ras activation of Elk-1 and AP-1/ATF tran-
scription factors depends on different effector pathways con-
* Corresponding author. Mailing address: Department of Molecular
Genetics, 484 West Twelfth Ave., The Ohio State University, Colum-
bus, OH 43210. Phone: (614) 688-3824. Fax: (614) 292-4466. Elec-
tronic mail address: mostrows@postbox.acs.ohio-state.edu.
538
 o
n
 O
ctober 26, 2015 by University of Queensland Library
http://m
cb.asm
.org/
D
ow
nloaded from
 
sisting of related but distinct protein kinases. The bifurcation
of Ras effectors and signaling is likely to at least partially
account for the disparate effects attributed to Ras both during
cell transformation and differentiation (36).
In addition to stimulating immediate-early gene expression,
Ras signaling can potentiate the stable expression of genes in
transformed cells or when activated by growth factor receptors
such as c-Fms. One class of enhancer element that is a target
for this type of prolonged Ras action is composed of binding
sites for Ets family members and AP-1/ATF family members
(5, 20). Dominant negative versions of c-Jun or c-Ets2 block
Ras mitogenic signaling (32, 34, 51), demonstrating that these
families of factors are necessary for Ras transformation. In the
case of the Ets2 dominant negative gene, signaling emanating
either from an activated ras oncogene or from c-fms activation
of endogenous Ras is affected (34). Many cellular genes have
now been demonstrated to contain a Ras-responsive enhancer
(RRE) composed of binding sites for both classes of these
nuclear factors (5, 20), and activation of such genes likely plays
a role in a diverse array of cellular processes (5).
As discussed above, AP-1/ATF family members are targets
for Ras signaling pathways and are likely to be involved in
regulating genes containing the composite Ets–AP-1 motif. In
transient assays, the Ets factors Ets1 and Ets2 have been shown
to collaborate with AP-1 factors in the activation of a reporter
that contained multiple copies of the polyomavirus (Py) onco-
gene-responsive enhancer (49). Additionally, in the proper
promoter context, Ets2 activation is enhanced by coexpression
of activated Ras (18, 53). Recently, it has been demonstrated
that the p68 form of Ets1 interacts with the POU homeodo-
main transcription factor PIT-1 to stimulate Ras-enhanced
activity of the prolactin promoter (7). However, there have
been no published reports concerning the mechanism of Ets
activation in mammalian cells. In the present report, we show
that Ets1 or Ets2 selectively collaborated with Ras in the ac-
tivation of Ets–AP-1 composite responsive elements, and Ets2
also activated an element composed of a palindromic Ets-Ets
composite site. Mutation of a critical threonine residue within
the amino-terminal domain conserved in Ets1 and Ets2 results
in abrogation of Ras and Ets synergism. Finally, we provide
biochemical evidence indicating this threonine residue is phos-
phorylated in response to Ras signaling. These results define a
molecular determinant in the Ets1 and Ets2 proteins necessary
for Ras action in establishing altered patterns of gene expres-
sion.
MATERIALS AND METHODS
Plasmids and site-directed mutagenesis. The reporter plasmids for NVL3
(39), urokinase-type plasminogen activator (uPA) (46), Py enhancer, and E.18
(18) have been previously described. The expression vectors for activated ras
were also previously described (18, 39). The human c-fms promoter used con-
tains 433 bp of sequence adjacent to the first ATG residue in exon 2 of the gene
and was constructed as described previously (40).
The human Ets2 influenza virus hemagglutinin-tagged vector and the vector
encoding the p54 form of chicken Ets1 have been previously described (40). The
FNpcDNA3 expression vector was constructed by using the cytomegalovirus
promoter-driven expression vector pcDNA3 (Invitrogen, San Diego, Calif.). Se-
quences that encoded the FLAG epitope tag, recognized by the FLAG M2
monoclonal antibody (Kodak/IBI, New Haven, Conn.), and the simian virus 40
T-antigen nuclear localization signal were inserted between the HindIII and
BamHI sites. The Ets2 coding sequence was directionally subcloned into this
vector as a BamHI-SalI fragment following addition of an in-frame BamHI site
at the 59 end and a SalI site just 39 of the termination codon. In all of the
transactivation assays, unmodified Ets2 expressed from the parent vectors be-
haved in the same manner as the epitope-tagged versions of Ets2 (data not
shown).
The mutations in p54 Ets1 and the hemagglutinin-tagged Ets2 expression
vectors were introduced by a PCR strategy that depended on the unique HpaI
site which included the codon for threonine 38 or threonine 72. One PCR primer
containing this HpaI site with the appropriate base change to alter the coding
sequence from threonine to different amino acids was used in combination with
a primer located 39 that encompassed either the EcoRV site or XmnI site
uniquely located in the ets1 or ets2 cDNA, respectively. Introduction of the
mutations resulted in the loss of the HpaI site. Mutations of FN-Ets2 constructs
that alter residue 72 were constructed by using a Chameleon site-directed mu-
tagenesis kit (Stratagene, La Jolla, Calif.) as recommended by the manufacturer.
The expression vectors for human Fli-1 (30) and mouse Elf-1 (33) were
previously described. The cDNA for murine PEA3 (54) was subcloned into the
hemagglutinin-tagged vector used for human Ets2 expression (see above).
Transfection assays. NIH 3T3 cells were grown in culture and transfected by
the calcium phosphate method exactly as described previously (18, 39). Growth
and electroporation of RAW264 cells were accomplished exactly as described
previously (46). For these experiments, expression vectors for Ets factors and
Ras were titrated to determine the level of plasmid that saturated reporter
activity. The amounts of plasmids used for the assays presented here including
the superactivation assays, were set at the saturating level. In general, these
amounts were 0.1 mg for Ets2 and other factors expressed using cytomegalovirus-
based vectors and 1 mg for Ets1 or Ras.
Immunoprecipitation and phosphoamino acid analysis. NIH 3T3 cells were
cotransfected with 5 mg of plasmid expressing wild-type or mutant FLAG
epitope-tagged Ets2 protein and either 2 mg of oncogenic Ras expression vector
or 2 mg of empty expression vector. At 20 h after addition of the calcium
phosphate precipitate, the medium (Dulbecco modified Eagle medium contain-
ing 10% calf serum) was removed and replaced with Dulbecco modified Eagle
medium containing 0.5% calf serum. The cells were then incubated for another
20 h. This treatment following transfection was the same as that used for trans-
activation analysis with the E.18 reporter construct. The serum-starved cells were
then washed and refed with phosphate-free medium containing 2 to 3 mCi of 32Pi
per ml. In the parallel experiments to analyze protein expression levels, the cells
were refed with methionine-free medium containing 200 mCi of [35S]methionine
per ml. After 4 h of incubation, the cells were washed and lysed with radioim-
munoprecipitation assay buffer for 20 min at 48C. The extract was collected and
precleared with rabbit preimmune serum for 1 h. The precleared extract was then
incubated with 8 mg of anti-FLAGM2 monoclonal antibody (IBI/Kodak) for 2 h,
and the antibody-antigen complex was precipitated with protein G-coated Sepha-
rose beads (GammaBind Plus; Pharmacia). The samples were separated on
sodium dodecyl sulfate 9% (SDS)–polyacrylamide gels, and the gel with the
35S-labeled samples was dried and analyzed by with a phosphoimager (Bio-Rad,
Richmond, Calif.).
The gel containing the 32P-labeled samples was electroblotted onto a polyvi-
nylidene difluoride membrane (Millipore, Bedford, Mass.), and the Ets2 band
was cut out and incubated in 50 ml of 6 N HCl for 80 min at 100 to 1108C. The
samples were diluted in deionized water and dried under vacuum. Phos-
phoamino acid analysis was performed as described previously (6). Briefly, the
samples were resuspended in formic acid-acetic acid buffer (pH 1.9). They were
then spotted onto cellulose plates, along with 1.0 mg each of phosphothreonine,
phosphoserine, and phosphotyrosine standards, and run on a Hunter thin-layer
electrophoresis unit (HTLE 7000; CBS Scientific, Inc., Del Mar, Calif.). The
samples were separated in the first dimension at pH 1.9 for 20 min at 1.5 kV and
then in the second dimension at pH 3.5 for 16 min at 1.3 kV. The standards were
visualized by spraying with 0.25% ninhydrin in acetone. The 32P-labeled amino
acids were visualized and quantitated with a phosphoimager. The data were
quantitated and displayed with Molecular Analyst software obtained from Bio-
Rad.
RESULTS
Superactivation of Ets–AP-1 RRE reporters by the combi-
nation of Ras and Ets1 or Ets2. The isolated DNA binding
domain of human c-Ets2 abolishes mitogenic signaling by Ras
or c-Fms and also blocks activation of downstream genes that
contain RREs composed of binding sites for Ets factors and
AP-1 (32, 51). While these data demonstrate the importance of
Ets family members in Ras signaling events crucial for cell
transformation, they do not identify which Ets family members
are involved because of the similarity in DNA binding sites for
Ets family proteins. To address this issue, we decided to iden-
tify which Ets family members could be activated by Ras. For
these experiments, we used five different reporter constructs in
transient transfection assays in NIH 3T3 fibroblasts (Fig. 1).
These reporters were transfected along with an expression
vector for Ras, Ets1, or Ets2 or the combination of Ras with
either Ets1 or Ets2.
The NVL3 RRE is a prototype viral RRE that contains an
Ets–AP-1 composite site (39). This enhancer (Fig. 1A) was
weakly activated by human Ets2 (two- to threefold induction)
or the p54 form of chicken Ets1 (four- to fivefold induction).
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As expected, the NVL3 RRE was strongly responsive to acti-
vated Ras (10-fold induction). However, the combination of
Ets1 or Ets2 and Ras stimulated NVL3 RRE activity 35- to
40-fold. (Fig. 1A). This effect, which we term superactivation,
was clearly more than the result of a simple additive effect of
Ets1 or Ets2 and Ras. When a farnesylation-negative Ras mu-
tation was used, no collaboration with Ets factors was observed
(data not shown). For the experiments using Ets2, a form of
the protein that was epitope tagged at the amino terminus with
an influenza virus-derived peptide was utilized (PGCN-E2; see
Materials and Methods). Identical results were obtained with
the human Ets2 cDNA without the epitope tag (data not
shown).
The cis sequence requirement for Ras-Ets superactivation in
a cellular gene was determined by using the uPA promoter
(Fig. 1B). This promoter contains an Ets–AP-1/ATF motif that
is located approximately 2,300 bp upstream of the transcription
initiation site of the promoter and has been previously identi-
fied as an element that responds to phorbol esters or other
growth factors such as epidermal growth factor (41) and col-
ony-stimulating factor 1 (46) and can also be transactivated by
coexpression of Ets2 (46). For the experiments presented in
Fig. 1B, a short DNA fragment containing the distal Ets–AP-
1/ATF element was placed immediately upstream of the prox-
imal uPA promoter at position 2110 (41), and this combina-
tion was linked to a firefly luciferase reporter gene. Enhancer
elements that contained point mutations in either the Ets-
related or AP-1-related sites (see Materials and Methods)
were also tested for Ras and Ets responsiveness. The data
indicated that the uPA distal element behaved as an RRE in
these assays and that the activity of this RRE depended on the
integrity of both Ets and AP-1/ATF sites (Fig. 1B). Addition-
ally, the native uPA RRE was superactivated nearly 30-fold by
the combination of Ras and Ets2. When Ets1 was substituted
for Ets2, a similar result was obtained (see below). The super-
activation by Ras and Ets2 depended on intact Ets and AP-1/
ATF binding sites, because the reporters containing mutations
in either of these sites were no longer superactivated. Similar
results were obtained with a reporter construct that contained
4 kb of the proximal uPA promoter with the RRE in its en-
dogenous position at 22300 (data not shown).
The stromelysin promoter contains an RRE composed of
two inverted Ets sites (50), and an artificial construct based on
this type of element, termed E.18, is a robust RRE reporter
(18). The superactivation of this element was determined in
parallel with the Ets–AP-1 Py prototype oncogene-responsive
enhancer (49). One copy of either of these elements was placed
in the identical reporter context (18). For these experiments, a
FLAG epitope-tagged form of Ets2 (FN-E2; see Materials and
Methods) was employed, but identical results were obtained
FIG. 1. Superactivation of RRE reporters by the combination of Ras with c-Ets1 or c-Ets2. (A) Activation of the NVL3 RRE luciferase reporter by c-Ets1 and
c-Ets2 (pGCN-E2) in NIH 3T3 cells in either the absence [(2)ras] or presence [(1)ras] of activated human Ha-c-Ras (1 mg). (B) Activation of uPA luciferase reporters
in NIH 3T3 cells by c-Ets2 (pGCN-Ets2), Ras, or the combination of the two, as indicated. The reporters used contained wild-type Ets–AP-1/ATF elements (uPA,
AGGAAATGAGGTCA), Ets site mutated [uPA(E-mut), AccAAATGAGGTCA], and AP-1/ATF site mutated [uPA(A-mut), AGGAAATGAGGagA]. (C) Activation
of the Py and E.18 CAT reporters by c-Ets2 (FN-E2) in the absence [(2)ras] or presence [(1)ras] of Ras. The E.18 site consists of an inverted repeat of an Ets motif
(GACCGGAACTACTTCCGGTC). (D) Activation of the c-fms proximal promoter in NIH 3T3 cells by Ets1 and Ets2 in the absence or presence of Ras, as indicated.
The 2430 human c-fms promoter (40) was used for these experiments. For all experiments, the averages of four separate experiments performed in duplicate are
presented, and error bars indicate standard deviations. For these experiments, the activity of the reporter in the presence of empty expression vectors (control lane)
was set to 1. Activity is expressed as relative luciferase activity (RLA).
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when an untagged Ets2 expression construct was used (data
not shown). The results obtained with the Py-chloramphenicol
acetyltransferase (CAT) reporter indicated that activation by
Ets2 or Ras alone and superactivation by the combination of
the two genes was virtually identical to what was seen with the
other two Ets–AP-1 reporters (3-, 10-, and 30-fold activation,
respectively; Fig. 1C). Ets1 did not efficiently activate the E.18
reporter either alone or in combination with Ras (data not
shown). However, the E.18 reporter was activated by Ets2 or
Ras to roughly the same extent but was superactivated by the
combination over 60-fold (Fig. 1C). Thus, either an Ets–AP-1
or Ets-Ets RRE element could be superactivated by Ras and
Ets-factors.
The murine and human c-fms promoters are transactivated
by Ets1 and Ets2, and an Ets2-responsive binding site in the
human promoter has been identified (40, 42). For these exper-
iments, we cotransfected the human c-fmsmacrophage-specific
promoter located in the first intron of the gene along with Ets
and Ras expression vectors (Fig. 1D). This promoter contained
430 bp of information located adjacent to the first coding
intron of the gene including the site identified as an Ets bind-
ing site (40). As described previously, this promoter responded
to cotransfection of an Ets1 or Ets2 expression plasmid with an
8- to 10-fold increase in reporter gene expression in NIH 3T3
fibroblasts. Cotransfection of activated Ras had no effect on
either basal or Ets-stimulated activity (Fig. 1D). The same
results were obtained when the macrophage cell line RAW264
was used (data not shown). The data demonstrate that the
c-fms Ets-responsive element is not an RRE.
Electrophoretic mobility shift assays (EMSA) using recom-
binant Ets2 protein and the binding sites from the uPA or E.18
reporter have demonstrated that Ets2 can directly interact with
these RREs (46). Likewise, recombinant Ets2 can bind to the
NVL3 RRE in vitro (data not shown). The EMSA results are
consistent with a direct in vivo interaction between Ets1 or
Ets2 and the various RREs used in the experiments described
above.
Selective superactivation of Ets1 and Ets2 by Ras. To de-
termine whether the effect of Ras and Ets1 or Ets2 was selec-
tive or a general property of the overexpression of Ets factors,
the abilities of other Ets family members, including human
Fli-1, mouse Elf-1, and mouse PEA3, to superactivate RRE
reporters were tested (Fig. 2). The experiments reported here
were conducted in the murine macrophage cell line RAW264.
These cells have 5- to 10-fold lower c-Ets2 mRNA than NIH
3T3 cells (data not shown). Consistent with the lower levels of
endogenous Ets2 mRNA, both Ets1 and Ets2 strongly acti-
vated the uPA reporter (20- and 13-fold activation, respective-
ly). Strikingly, the combination of Ets1 and Ets2 with Ras
activated this reporter 80- to 100-fold. In contrast, Fli-1 acti-
vated the reporter sixfold, while Elf-1 or PEA3 activated the
uPA reporter only two- to threefold, and none of these factors
displayed superactivation in combination with Ras; in fact,
PEA3 partially blocked Ras activation of the uPA reporter.
Results similar to those represented in Fig. 2 were obtained for
NIH 3T3 cells when either the uPA or NVL3 reporter was used
(data not shown). It is unlikely that the lack of Ras superacti-
vation of PEA3 or Elf-1 was due to their inability to bind
RREs, because when these proteins were expressed in COS
cells, EMSAs with RRE probes revealed that new specific
complexes were formed (data not shown). Analysis of steady-
state expression of the epitope-tagged version of the PEA3 and
Ets2 proteins used in these experiments (see Materials and
Methods) indicated that the two proteins were expressed at the
same level, indicating that for PEA3, lower levels of protein
expression are not the reason for the absence of Ras respon-
siveness. Together, the results indicated that the superactiva-
tion of reporters by Ets1 or Ets2 and Ras is highly selective.
In addition to the Ets domain, which is 95% conserved
between Ets1 and Ets2, these two proteins also share a region
of homology of over 100 amino acids present in their amino-
terminal regions (52) (Fig. 3A). This region of homology is also
shared with the Drosophila Ets family member Pointed and has
been termed the Pointed domain (29). Within the first 30
amino acids of this region, a potential kinase phosphorylation
site, PLLTP, was found in both Ets1 and Ets2 (Fig. 3B). A
similar sequence (PPLTP) is found at the same position of the
Drosophila pointed P2 product and has been shown to be func-
tionally important (8, 38). These sites are related to the pub-
lished consensus site for MAP kinases p42 and p44 (1). These
observations indicate that the amino-terminal sequence
PLLTP may be critical for common behavior of Ets1 and Ets2
in the transient Ras superactivation assays (see above).
Mutation of the potential phosphorylation site threonine 38
in Ets1 or threonine 72 in Ets2 abrogates Ras superactivation.
To test the importance of the potential MAP kinase phosphor-
ylation site in Ets1 and Ets2 in the Ras superactivation of RRE
FIG. 2. Superactivation of RRE activity by Ras and Ets factors is selective.
The activity of the uPA luciferase reporter was measured in RAW264 cells in the
presence of Ets1, Ets2 (PGCN-E2), Fli-1, Elf-1, or PEA3, as indicated, in the
absence [(2)ras] or presence [(1)ras] of Ras. The averages of four experiments
performed in duplicate are presented, and the error bars indicate standard
deviations. The activity of the reporter in the presence of empty expression
vectors (control lane) was set to 1. RLA, relative luciferase activity.
FIG. 3. An N-terminal domain conserved in c-Ets1 and c-Ets2. (A) Illustra-
tion of the Ets2 protein, with the amino-terminal conserved Pointed domain as
well as the carboxy-terminal Ets domain highlighted. (B) Comparison of the
sequences of Ets2, Ets1, and Pointed surrounding the putative kinase substrate
region. The conserved threonine residue, a potential MAP kinase site, is indi-
cated by p.
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reporters, the threonine residue within this site was mutated to
an alanine residue by PCR-based site-directed mutagenesis
(see Materials and Methods). This threonine residue occurs at
position 38 in Ets1 (p54 [52]) and at position 72 in Ets2. The
expression vectors encoding these mutations were cotrans-
fected along with the NVL3 reporter and Ras into NIH 3T3
cells (Fig. 4A and B, respectively). In each case, the single
point mutations only slightly reduced the ability of Ets1 and
Ets2 proteins to transactivate the NVL3 RRE. In addition, the
alanine-mutated versions of Ets1 and Ets2 were able to acti-
vate the c-fms promoter as well as the wild-type versions of the
proteins (data not shown). Conversely, the ability to collabo-
rate with activated Ras was completely ablated. From 30- to
40-fold superactivation with wild-type Ets1 or Ets2, activation
fell to the same level observed with Ras alone when the alanine
38 (Fig. 4A) or alanine 72 (Fig. 4B) mutation was tested. By
analogy to other transcription factor targets of the MAP kinase
superfamily, we predicted that if the Ets2 threonine 72 was
substituted with a serine residue, this site of Ets2 would retain
its ability to be phosphorylated. The Ets2 serine 72 protein was
fully competent in superactivation of the reporter gene, and in
fact, the serine 72 version was slightly more active than the
wild-type Ets2 protein (44-fold superactivation, compared with
35-fold for the wild type). We also tested whether substitution
of Ets2 threonine 72 with an acidic residue (aspartic acid)
could partially mimic the phosphorylated threonine and lead to
a higher basal level of reporter gene activation. The Ets2 as-
partic acid 72 mutation created a protein with slightly higher
basal-level activity (fivefold activation, compared with three-
fold for the wild-type Ets2 protein) but one that could not
participate in superactivation (average of 11-fold activation,
compared with 10-fold for Ras alone). Similar results were
obtained when the uPA promoter was assayed with the Ets1
and Ets2 mutations in either NIH 3T3 or RAW264 cells (data
not shown).
Superactivation of Ets-Ets RRE reporters by the combina-
tion of Ras and Ets2. To determine whether Ets2 is an inde-
pendent target for Ras-mediated superactivation in the ab-
sence of an adjacent AP-1 binding site, the E.18 reporter was
also used to test the Ets2 mutations in NIH 3T3 cells. The
RRE in E.18 consists of two inverted Ets2 consensus binding
sites and no AP-1 binding site (18). As with the NLV3 re-
porter, conversion of the Ets2 threonine 72 to alanine only
slightly reduced responsiveness to Ets2 alone but resulted in
complete loss of the previously high superactivation of the E.18
reporter mediated by Ras and Ets2 in combination (Fig. 4C).
An Ets2 serine 72 factor was effective in the E.18 superactiva-
tion assay, while a glutamic acid 72 acidic residue conversion
resulted in a slight increase in basal-level activation but loss of
superactivation potential. The Py reporter, containing the
overlapping Ets and AP-1 sites in the same context as the E.18
RRE, behaved in a similar manner with these Ets2 mutations
when tested in NIH 3T3 cells (data not shown).
The absence of a significant effect of these mutations on the
basal-level activity of Ets1 and Ets2 assayed on the RRE re-
porters as well as the c-fms promoter implied that the mutated
proteins are expressed and folded properly. However, alter-
ations in the level of expression, protein localization, or DNA
binding of alanine-substituted Ets1 and Ets2 could still account
for these results. Thus, experiments were performed to assess
possible changes in these properties of the Ets2 alanine 72-
mutated protein. Following transient transfection of expres-
sion constructs for either wild-type or alanine 72 Ets2 into NIH
3T3 cells, cellular proteins were metabolically labeled with
[35S]methionine and Ets2 expression was determined by im-
munoprecipitation. The epitope tag on the expressed Ets2 al-
lowed the transfected protein to be distinguished from the
endogenous protein. The conditions for these experiments
were the same as in the transient transfections assays (see
above) and the 32P labeling experiments (see below). As dem-
onstrated in Fig. 5, activated Ras increased the expression of
FIG. 4. Mutation of threonine 38 in Ets1 or threonine 72 in Ets2 abrogates
Ras superactivation activity. (A) Activity of the NVL3 luciferase reporter in NIH
3T3 cells in either the absence [(2)ras] or presence [(1)ras] of activated Ha-c-
Ras. An expression vector for wild-type threonine 38 Ets1 or mutated alanine 38
Ets1 was included as indicated. (B) Activity of the NVL3 luciferase reporter in
NIH 3T3 cells in either the absence [(2)ras] or presence [(1)ras] of activated
Ha-c-Ras. An expression vector for wild-type threonine 72 Ets2 (PGCN-E2) or
mutated Ets2 form alanine 72, serine 72, or aspartic acid 72 was included as
indicated. (C) Activity of the E.18 CAT reporter in NIH 3T3 cells in either the
absence [(2)ras] or presence [(1)ras] of activated Ras. An expression vector for
wild-type threonine 72 Ets2 (FN-E2) or mutated Ets2 form alanine 72, serine 72,
or glutamic acid 72 was included as indicated. For all experiments, the averages
of four separate experiments performed in duplicate are presented, and error
bars indicate standard deviations. For these experiments, the activity of the
reporter in the presence of empty expression vectors (control lane) was set to 1.
Activity is expressed as relative luciferase activity (RLA).
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proteins from the FN-Ets2 vectors approximately threefold,
but equal amounts of wild-type and alanine 72 Ets2 proteins
were present in the cells, indicating that protein folding and
the steady-state protein concentration were not greatly af-
fected by mutation of residue 72. In addition, because the Ets2
alanine 72 protein did not participate in superactivation, sim-
ply increasing the amount of Ets2 protein cannot account for
Ras superactivation. This interpretation is reinforced by exper-
iments in which Ets2 protein levels were increased in the ab-
sence of Ras by simply increasing the amount Ets2 expression
plasmid in the transient transfection assay. Increasing Ets2
levels three to fivefold in this way (as determined by Western
blotting) did not result in superactivation of the E.18 reporter
(data not shown). Immunohistochemical analysis following
transient expression demonstrated that both wild-type and ala-
nine 72 Ets2 proteins were located in the nucleus, indicating
that this mutation did not affect cellular localization (data not
shown). Finally, EMSA with wild-type and alanine 72 proteins
expressed in COS cells or by coupled in vitro transcription-
translation demonstrated that the two proteins bind the RREs
with approximately equal affinities (data not shown).
Ras-dependent phosphorylation of threonine 72 in the Ets2
transcription factor. The functional data presented above
demonstrated that the threonine residues present at position
72 in Ets2 and position 38 in Ets1 were critical for Ets-Ras
superactivation of RRE reporters and implicated the threo-
nine 72 and threonine 38 residues of these Ets factors as
targets of Ras-dependent phosphorylation. To examine more
directly the Ras-dependent phosphorylation of threonine 72 in
Ets2, transfection experiments with epitope-tagged Ets2 (FN-
E2) in either the presence or absence of expression of activated
ras oncogene were performed. Transfected cells were labeled
in parallel with [35S]methionine or 32Pi, and the exogenous
Ets2 was immunoprecipitated (see Materials and Methods).
Antibodies that recognize the FLAG epitope of the expressed
Ets2 protein were used for immunoprecipitation of the Ets2
protein from the 32P-labeled cell extract. The immunoprecipi-
tate was run on an SDS-polyacrylamide gel and transferred to
a polyvinylidene membrane, and the Ets2 band was identified
and eluted. Subsequently, equivalent amounts of 32P-labeled
Ets2 protein were subjected to phosphoamino acid analysis,
and the results were analyzed on a phosphoimager (see Mate-
rials and Methods). The results of a typical experiment are
presented in Fig. 6. These data demonstrated that Ets2 was
extensively phosphorylated on serine residues, and comparison
of Ets2 protein levels and 32P incorporation (Fig. 6A and B)
indicated that Ras coexpression produced no large change in
total Ets2 serine phosphorylation. In contrast, phosphothreo-
nine was not detected in Ets2 protein isolated from cells that
lacked Ras expression (Fig. 6A), but threonine phosphoryla-
tion was induced by Ras coexpression (Fig. 6B). When the
alanine 72 version of Ets2 was substituted for the wild-type
protein in this assay, abundant serine phosphorylation was
again detected independent of Ras expression. However, Ras-
dependent threonine phosphorylation was no longer detected
with the alanine 72 mutation (Fig. 6C and D). Further, when
the serine 72 mutation, which can participate in superactiva-
tion, was examined in this assay, phosphothreonine was again
not detected (Fig. 6E and F). For the serine 72 mutation, no
change in Ras-dependent serine phosphorylation was detected
above the high background of serine phosphorylation already
present. This analysis was performed multiple times with iden-
tical results. Taken together, these data indicate that threonine
72 is the only site of Ras-dependent threonine phosphorylation
present in the Ets2 protein and, consistent with the functional
results presented in Fig. 4, that phosphorylation of threonine
72 is necessary for Ras activation.
DISCUSSION
The integration of signal transduction pathways and tran-
scriptional components in the regulation of immediate-early
genes has been delineated in some detail by recent work in a
number of systems (23). Studies on the c-fos promoter provide
one example in which the Ets factor Elk-1/SAP-1 has been
demonstrated to be a direct target of Ras/MAP kinase p42/p44
signaling that is necessary for the transient, immediate-early
transcription of c-fos (23). A less defined problem is how sig-
1 2 3 4 5 6 7
Ets2 T72
 (wt) Ets2 A72 Ets2 S72
Ras+ + +_ _ _ _
Ets2
FIG. 5. Mutation of threonine 72 of c-Ets2 to alanine 72 does not grossly affect protein folding or steady-state concentrations. Comparison of Ets2 threonine 72,
alanine 72, and serine 72 expressed following transient transfection of NIH 3T3 cells. Cells were transiently transfected with the indicated FN-Ets2 expression vector
and, where indicated by 1, an expression construct for oncogenic Ras. At 40 h after transfection, the cells were metabolically labeled with [35S]methionine for 4 h, and
then the exogenous Ets2 was immunoprecipitated with either nonimmune serum (lane 1) or the anti-FLAG monoclonal antibody directed against the epitope tag of
Ets2 (lanes 2 to 7). The precipitated proteins were separated by SDS-polyacrylamide gel electrophoresis and visualized with a phosphoimager, and data were quantitated
and displayed with Molecular Analyst software obtained from Bio-Rad. wt, wild type.
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naling pathways lead to the stable, persistent expression of
genes. The regulation of such genes is crucial to the final
phenotype of cells both during terminal differentiation and
during neoplastic progression. Studies involving the transcrip-
tional enhancer elements present in genes that are regulated in
response to growth factor and Ras signaling have linked Ets
factors with the persistent regulation of genes in transformed
cells (5, 18, 32) and during macrophage differentiation (25). In
the present report, Ets1 and Ets2 are more directly implicated
as nuclear targets of Ras signal transduction pathways in mam-
malian cells, indicating that Ets family members play central
roles in stable as well as transient gene expression regulated by
Ras signaling pathways.
Ets1 and Ets2 are capable of collaborating with an activated
Ras product to superactivate enhancers containing Ets–AP-1
composite elements or, in the case of Ets2, the E.18 Ets-Ets
element. The data for the E.18 promoter indicate that Ets2 is
a direct target of the Ras signaling pathway and not an auxil-
iary factor necessary for correct AP-1/ATF function. Although
activated Ras does increase the level of expression of Ets2
Ser
Thr
Tyr
ThrThr
Thr
Thr
Thr
Ala72
Ser72
- Ras + Ras
(Thr72)
wt
A B
C D
E F
FIG. 6. Phosphorylation of threonine 72 in c-Ets2 in response to Ras signaling. An FN-E2 expression vector encoding the threonine 72 (A and B), alanine 72 (C
and D), or serine 72 (E and F) version of Ets2 was cotransfected into NIH 3T3 cells with an expression construct for oncogenic Ras (1Ras) or with an empty Ras
expression vector (2Ras). After 40 h, the transfected cells were metabolically labeled with 32Pi for 4 h, and the exogenous Ets2 was immunoprecipitated with an
antibody against the FLAG epitope tag. Phosphoamino acid analysis was performed as described in Materials and Methods. The dotted circles indicate in panel A the
positions, following chromatography and ninhydrin detection, of the phosphoserine, phosphothreonine, and phosphotyrosine standards and in panels B to F the
positions of the phosphothreonine standard. The data were quantitated and displayed with Molecular Analyst software obtained from Bio-Rad.
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from the cytomegalovirus-driven expression plasmids three- to
fivefold, the synergism between the two cannot be attributed to
this effect alone. First, the Ets2 alanine 72 mutation did not
alter the level of protein expression but abolished reporter
gene superactivation in combination with Ras. Second, the
synergism is not seen with all Ets2-responsive promoters; for
example, the c-fms promoter is Ets responsive but not Ras
responsive, and the alanine 72 mutation has no effect on Ets2
activation of the c-fms promoter. This observation indicates
that the promoter context is critical for Ras-Ets collaboration
to be evident. These results also provide an important control
demonstrating the integrity of the mutated Ets factors as well
as the specific role of phosphorylation of the conserved threo-
nine residues in Ras-activated signaling. Finally, Ets2 expres-
sion can be amplified independently of Ras action by increas-
ing the amount of expression plasmid cotransfected with the
reporter. Increasing Ets2 expression by three- to fivefold in this
way does not lead to reporter superactivation (55).
Several other Ets factors, including Fli-1, Elf-1, and PEA3,
do not collaborate with Ras in enhancer regulation. Compar-
ison of the sequences of Ets1 and Ets2 indicated that a previ-
ously recognized homology of approximately 100 amino acids
in the N-terminal regions of both proteins (52) might be re-
sponsible for the common behavior of the two factors in the
assays reported here. The molecular genetic data presented
support the view that phosphorylation of a potential MAP
kinase site (PLLTP [1]) at position threonine 38 or threonine
72 in Ets1 or Ets2, respectively, is critical for the ability of these
factors to collaborate with Ras in superactivation of RRE
reporters.
Because members of the MAP kinase family can inter-
changeably phosphorylate either threonine or serine residues
in the proper context, we tested mutants that alter Ets-2 threo-
nine 72 to serine, which could potentially be phosphorylated,
or to alanine or glutamic acid, which could not be phosphor-
ylated. Only the Ets2 serine 72 mutant could collaborate with
Ras. Additionally, biochemical evidence implicates threonine
72 of Ets2 as the sole Ras-dependent site of threonine phos-
phorylation in vivo. Phosphothreonine in Ets2 was detected in
the presence of activated Ras but was absent in the Ets2 ala-
nine 72 mutant coexpressed with Ras. Furthermore, our find-
ing that the serine 72 mutant of Ets2 is fully functional in
collaborating with Ras, yet contains no phosphothreonine when
coexpressed with Ras, strongly suggests that residue 72 is not
just a recognition sequence for the kinase but is in fact the site
of Ras-induced threonine phosphorylation in wild-type Ets2
protein. These data reveal that the conserved phosphorylation
site is necessary for the phenomenon of enhancer superactiva-
tion. As Ras-dependent phosphorylation of serine sites in
these proteins cannot be ruled out by the data presented here,
phosphopeptide mapping studies will be required to determine
if serine phosphorylation of Ets2 occurs in response to Ras
signaling events.
It has recently been reported that the p68 form of Ets1 can
collaborate with Ras and the transcription factor PIT-1 in the
activation of the prolactin promoter, and the portion of p68
Ets1 responsible for collaboration with Ras was roughly
mapped within the highly conserved Pointed domain (7). How-
ever, in contrast to our results with the RRE reporters, Ets2
was incapable of activating this promoter in either the absence
or presence of Ras (7). This difference may be attributed to
interactions between Ets1 and PIT-1 not mimicked by Ets2 and
thus be a specific example of protein-protein interactions gov-
erning whether a promoter that contains Ets factor binding
sites will be Ras responsive. This hypothesis can also account
for the difference in activation by Ets1 and Ets2 of the E.18
reporter used here as well as for the inability of Ets1 to activate
the scavenger receptor Ets–AP-1 enhancer in F9 embryonal
carcinoma cells (53). Therefore, Ras-dependent phosphoryla-
tion likely alters the interaction of Ets1 and Ets2 with other
nuclear factors. This altered protein association could increase
the binding affinity of Ets1 and Ets2 for a particular recogni-
tion site, increase the transactivation potential of Ets1 and Ets2
located at a particular recognition site, or affect both proper-
ties.
Differentiation of the photoreceptor R7 cell in the develop-
ing Drosophila eye is controlled by a Ras signaling pathway
(43). The components of the fly Ras signaling pathway are
remarkably conserved between flies and mammals, and the
genetic analysis of this invertebrate system has been critical in
unraveling many long-standing issues in the mammalian Ras
field (reviewed in reference 17). Thus, analysis of the Drosoph-
ila factor Pointed (8, 38) provided a precedence for our studies
of Ets1 and Ets2. Our data extend to mammalian cells the
evidence for the importance of the Pointed domain, and in
particular the conserved threonine phosphorylation site, in
Ras-Ets collaboration in mammalian cells. In addition, our
work advances the observations made in Drosophila studies in
two ways. First, the use of elements from genes known to be
targets of Ras signaling, instead of the artificial reporters used
in the Drosophila work (38), highlights the critical nature of
promoter context in the activation of Ets activity by Ras. Sec-
ond, our data provide evidence that the crucial threonine res-
idue is phosphorylated in response to Ras in vivo, data only
inferred from genetic and in vitro studies in the case of Dro-
sophila Pointed.
The sequence of the proline-flanked site and homology to
the Drosophila Ras signaling pathway of indicate that a MAP
kinase family member is likely responsible for phosphorylation
of threonine 38 and threonine 72 of Ets1 and Ets2, respec-
tively. Consistent with this idea, a glutathione S-transferase
fusion protein that contained the 100 amino acid region of
homology was a weak substrate (in comparison with myelin
basic protein) for MAP kinase p44 in vitro (55). However,
MAP kinases p42 and p44 did not synergize with Ras in the
superactivation assay, and kinase-defective forms of these
genes did not interfere with Ras activation of the RRE report-
ers (55). Thus, it is likely that the threonine 72/threonine 38 Ets
kinase is a distinct member of the MAP kinase family.
At present, three different MAP kinase signaling pathways
have been identified (13, 14, 16, 37). Two of these MAP kinase
pathways, the Raf/MEK-1/MAPK p42/p44 and the MEKK-1/
MEKK4/JNK branches, can be activated by the Ras-GTP com-
plex (16, 37). Additionally, data indicating that Ras may alter
cell morphology via activation of phosphatidylinositol 3-kinase
have been presented (31). Determining the identity of the Ets
kinase and the cascade leading to its activation will determine
whether it represents a distinct Ras signaling pathway. The
identification of a molecular target for Ras signaling in Ets2
described here will now allow the characterization of upstream
members of the Ets signaling pathway. The biological rele-
vance of the activation of Ets proteins by oncogenic Ras is
indicated by the finding that dominant inhibitory Ets mutations
can reverse Ras-mediated cellular transformation without
blocking normal cell growth (32, 51). The identity of genes
activated by this Ras/Ets pathway suggests that their altered
expression may play a crucial role in neoplastic transformation
(2, 5). For example, the extracellular proteases uPA and
stromelysin, whose promoters contain the Ras-Ets-responsive
elements described here, have been implicated in the process
of tumor cell invasion and metastasis (9). Describing the mo-
lecular mechanism of activation of Ets1 and Ets2 by Ras
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should provide new insights into how Ras controls cellular
phenotypes distinct from cell cycle regulatory events during
tumorigenesis and may provide new targets for inhibiting these
biological processes.
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